Valuation: AstraZeneca Pharma India Limited

Market Cap 151B 1.57B 1.39B 1.3B 1.19B 2.24B 2.26B 15.74B 6.1B 77.07B 5.89B 5.76B 247B P/E 2025
186x
P/E 2026 103x
Enterprise Value 147B 1.53B 1.36B 1.27B 1.16B 2.19B 2.21B 15.39B 5.96B 75.35B 5.76B 5.63B 242B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
18.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-1.55%
1 week-5.45%
Current month-4.02%
1 month-13.33%
3 months-27.91%
6 months-23.57%
Current year-34.24%
1 week 5,917
Extreme 5917
6,355
1 month 5,917
Extreme 5917
6,994
Current year 5,917
Extreme 5917
9,220
1 year 5,917
Extreme 5917
9,849.5
3 years 4,475
Extreme 4475
10,691
5 years 2,445.7
Extreme 2445.7
10,691
10 years 880.2
Extreme 880.2
10,691
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Compliance Officer - 23/02/2026
Chief Tech/Sci/R&D Officer - 03/03/2025
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 52 30/09/2024
Director/Board Member - 09/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-5.45% - - 1.57B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+0.85%-1.86%+20.94%+41.39% 333B
+1.05%-2.88%+11.34%+35.05% 267B
+0.30%-4.64%-6.40%+9.26% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.24%-3.54%+26.18%+58.89% 410.8B
Weighted average by Cap. -0.15%-3.54%+29.15%+70.72%

Financials

2025 2026
Net sales 17.16B 179M 159M 148M 135M 255M 257M 1.79B 694M 8.77B 670M 656M 28.16B 22.76B 237M 210M 196M 179M 337M 341M 2.38B 921M 11.63B 889M 869M 37.33B
Net income 1.16B 12.04M 10.7M 9.98M 9.1M 17.16M 17.32M 121M 46.82M 592M 45.2M 44.22M 1.9B 1.88B 19.51M 17.33M 16.18M 14.74M 27.81M 28.07M 196M 75.86M 959M 73.24M 71.65M 3.08B
Net Debt -5B -52.05M -46.25M -43.17M -39.35M -74.2M -74.9M -522M -202M -2.56B -195M -191M -8.21B -3.37B -35.06M -31.15M -29.08M -26.5M -49.98M -50.45M -352M -136M -1.72B -132M -129M -5.53B
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
05/10/26 ₹5,937.50 -1.55% 4,624
01/10/26 ₹6,031.00 -2.51% 11,473
30/09/26 ₹6,186.00 -1.10% 56,730
29/09/26 ₹6,254.50 -0.41% 8,506
28/09/26 ₹6,280.00 -3.46% 10,121
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A